Accuray Incorporated has announced that the first studies validating the benefits of the leading-edge Radixact System were presented at the 59th Annual Meeting of the American Association of Physicists in Medicine (AAPM) held in Denver, Colorado, July 30 to Aug. 3. This smart radiation therapy system represents the next generation in TomoTherapy treatment delivery, significantly increasing treatment speed and ease of use. The Radixact System enables clinicians to treat a wide range of cancer cases, from initial plan delivery to adaptive therapy to complex retreatments, with precision and increased efficiency.
Research highlights include:
Faster planning and shorter treatment time
A study evaluated the performance of the Radixact System based on a comparison of treatment plans developed for this system and the TomoHDA System. Treatment plans were created using the VoLO Planning Solution for the TomoHDA technology, then recreated using the Accuray Precision Treatment Planning System (TPS) for the Radixact System. Developing optimal plans using the Accuray Precision TPS was much faster, and the treatment beam-on time was reduced by up to 50% while maintaining the excellent plan quality. Researchers at the Miami Cancer Institute in Miami, Florida and Accuray Incorporated conducted the research.
Proven image quality and stability
The first clinical assessment of Radixact low-dose fan beam MVCT image guidance found there was no statistically significant difference in the noise, uniformity, and Hounsfield units (HU) stability over the three-month evaluation period, demonstrating the strength of the System's MVCT image quality and its potential value for dose calculation. Clinicians at the Miami Cancer Institute team conducted the research.
Radixact and TomoTherapy System dosimetric beam characteristics were compared over a six-month period. Radixact data were within the specifications established for the TomoTherapy System and showed a good agreement with the beam model. These results indicate that the beam commissioning process will be straightforward for the Radixact System. Researchers at Miami Cancer Institute and Accuray conducted the study.
The future of radiation therapy
Two studies demonstrated the feasibility of real-time motion management leveraging the TomoTherapy System’s one-of-a-kind helical delivery capabilities.
“The data presented at this year'’s AAPM speak to the precision, accuracy and effectiveness of Accuray's entire portfolio of radiation therapy systems,” said Calvin Maurer, PhD, vice president and chief technology officer at Accuray. “The Radixact System findings reinforce what customers are experiencing in their day-to-day practice and demonstrate its value to the radiation oncology team and their patients. In partnership with our customers we are continuing to develop clinically relevant technological advances such as the Radixact System, PreciseART Adaptive Solution and PreciseRTX Retreatment Option, which make it easier for clinicians to provide patients with the best possible treatment for them at each stage of their cancer treatment journey.”Back To Top
AAPM 2017: First Accuray Radixact System research results presented . Appl Rad Oncol.